Navellier & Associates Inc Catalyst Pharmaceuticals, Inc. Transaction History
Navellier & Associates Inc
- $792 Million
- Q4 2024
A detailed history of Navellier & Associates Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Navellier & Associates Inc holds 14,163 shares of CPRX stock, worth $308,895. This represents 0.04% of its overall portfolio holdings.
Number of Shares
14,163
Previous 12,294
15.2%
Holding current value
$308,895
Previous $244,000
20.9%
% of portfolio
0.04%
Previous 0.03%
Shares
10 transactions
Others Institutions Holding CPRX
# of Institutions
348Shares Held
98.5MCall Options Held
13.4KPut Options Held
11.7K-
Black Rock Inc. New York, NY18.7MShares$408 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.43MShares$184 Million0.0% of portfolio
-
State Street Corp Boston, MA5.8MShares$126 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.13MShares$68.3 Million1.62% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.01MShares$65.7 Million0.02% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.24B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...